The LIFR Inhibitor EC359 Effectively Targets Type II Endometrial Cancer by Blocking LIF/LIFR Oncogenic Signaling.
Spencer N, Rodriguez Sanchez AL, Gopalam R, Subbarayalu P, Medina DM, Yang X, Ramirez P, Randolph L, Aller EJ, Santhamma B, Rao MK, Tekmal RR, Nair HB, Kost ER, Vadlamudi RK, Viswanadhapalli S.
Spencer N, et al. Among authors: rao mk.
Int J Mol Sci. 2023 Dec 13;24(24):17426. doi: 10.3390/ijms242417426.
Int J Mol Sci. 2023.
PMID: 38139260
Free PMC article.